Researchers at Wake Forest School of Medicine have discovered that a nanoparticle therapeutic enhances cancer immunotherapy and is a possible new approach in treating malignant pleural effusion (MPE).
Phase II, open-label study of erlotinib (ERL) in patients with NSCLC with activating mutations of the EGFR identified on tissue samples, plasma DNA, and CTC-trigger. This is an ASCO Meeting Abstract ...
A novel dosing schedule with gemcitabine, vinorelbine, and carboplatin for advanced non-small cell cancer of the lung No significant financial relationships to disclose. This is an ASCO Meeting ...
Researchers have discovered that a nanoparticle therapeutic enhances cancer immunotherapy and is a possible new approach in treating malignant pleural effusion (MPE). MPE is the accumulation of fluid ...
Use of routine thoracentesis in addition to medical therapy yielded no significant benefits for adults with heart failure and pleural effusions, according to a new study. For patients with acute heart ...
Identifying and analyzing volatile organic compounds in exhaled breath of patients with malignant pleural mesothelioma showed promise as a screening method for MPM, according to research presented ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback